CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025
Rhea-AI Summary
CorMedix (Nasdaq: CRMD) will report third-quarter 2025 financial results for the period ended September 30, 2025, before the market opens on November 12, 2025, and will host a corporate update conference call at 8:30 AM ET that day.
The company is commercializing DefenCath for prevention of catheter-related bloodstream infections in adult hemodialysis patients and, following its August 2025 acquisition of Melinta Therapeutics, is commercializing a portfolio of anti-infective products (including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, KIMYRSA) and TOPROL-XL.
CorMedix has ongoing DefenCath studies in total parenteral nutrition and pediatric populations, and REZZAYO has an ongoing Phase III prophylaxis study with topline results expected in Q2 2026.
Positive
- Acquisition completed in August 2025 expands anti-infective portfolio
- Commercializing DefenCath for catheter-related bloodstream infection prevention
- REZZAYO approved for candidemia and invasive candidiasis in adults
- REZZAYO Phase III topline results expected in Q2 2026
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, CRMD declined 4.22%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
BERKELEY HEIGHTS, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the third quarter ended September 30, 2025, before the market opens on Wednesday, November 12, 2025, and will host a corporate update conference call at 8:30am Eastern Time.
| Wednesday, November 12th @ 8:30am ET | |
| Domestic: | 1-844-676-2922 |
| International: | 1-412-634-6840 |
| Webcast: | Webcast Link |
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath® (taurolidine and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter. Following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix is also commercializing a portfolio of anti-infective products, including MINOCIN® (minocycline), REZZAYO® (rezafungin), VABOMERE® (meropenem and vaborbactam), ORBACTIV™ (oritavancin), BAXDELA® (delafloxacin), and KIMYRSA® (oritavancin), as well as TOPROL-XL® (metoprolol succinate).
CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition and Pediatric patient populations and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of IFD in adult patients undergoing allogeneic BMT. Topline results of the Phase III study for REZZAYO are expected in Q2 2026. For more information visit: www.cormedix.com or www.melinta.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
When will CorMedix (CRMD) report Q3 2025 results and hold its investor call?
What products did CorMedix add with the August 2025 Melinta acquisition (CRMD)?
What is DefenCath and which patients is CorMedix (CRMD) commercializing it for?
When does CorMedix expect REZZAYO Phase III topline results and for what indication?
How can investors join the CorMedix (CRMD) November 12, 2025 webcast and call?
